Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.160
-0.360 (-23.68%)
At close: Mar 28, 2025, 4:00 PM
1.100
-0.060 (-5.17%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Plus Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Plus Therapeutics stock have an average target of 11.17, with a low estimate of 5.50 and a high estimate of 19. The average target predicts an increase of 862.93% from the current stock price of 1.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Plus Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $5.5 | Strong Buy | Maintains | $8 → $5.5 | +374.14% | Mar 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +675.86% | Mar 28, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $9 | Strong Buy | Maintains | $9 | +675.86% | Mar 21, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +675.86% | Mar 17, 2025 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $20 → $19 | Strong Buy | Maintains | $20 → $19 | +1,537.93% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
4.89M
from 5.82M
Decreased by -15.97%
Revenue Next Year
n/a
from 4.89M
EPS This Year
-1.52
from -2.34
EPS Next Year
-1.54
from -1.52
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.1M | n/a | 57.0M | ||
| Avg | 4.9M | n/a | 21.1M | ||
| Low | 3.5M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.5% | - | - | ||
| Avg | -16.0% | - | - | ||
| Low | -39.4% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.18 | -1.22 | -0.12 | ||
| Avg | -1.52 | -1.54 | -1.91 | ||
| Low | -1.62 | -2.15 | -3.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.